Is GTBP or GYRE more undervalued in 2026?

CirclFi compares GT Biopharma, Inc. (GTBP) and Gyre Therapeutics, Inc. (GYRE) using 13 institutional-grade valuation models. GTBP has a Quality of Company score of 3.5/10 while GYRE scores 8.0/10.

Which is a better buy — GTBP or GYRE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GTBP and GYRE valuations compare?

GTBP at $0.45 and GYRE at $5.74 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GTBP vs GYRE Valuation Comparison 2026 — Intrinsic Value Analysis

GTBP

Biotechnology

GT Biopharma, Inc.

Quality

3.5

out of 10

Value Trap

SAFE

Price

$0.45

Last close

Models

8/13

Active

GYRE

Biotechnology

Gyre Therapeutics, Inc.

Quality

8.0

out of 10

Value Trap

SAFE

Price

$5.74

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	GTBP Fair Value	GTBP Upside	GYRE Fair Value	GYRE Upside
Bayesian DCF	Intrinsic	$0.25	-42.8%	$0.52	-90.9%
Earnings Power Value	Intrinsic	—	—	$0.74	-87.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$0.06	-83.6%	—	—
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GTBP vs GYRE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GTBP vs GYRE — Which Stock Is More Undervalued?

GYRE scores higher with a 8.0/10 quality rating vs GTBP's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing GT Biopharma, Inc. (GTBP) and Gyre Therapeutics, Inc. (GYRE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GTBP currently trades at $0.45 with a QOC of 3.5/10, while GYRE trades at $5.74 with a QOC of 8.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).